Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk

Progress in Cardiovascular Diseases

Volumn 58, Issue 2, 2015, Pages 177-194

  Potpara, Tatjana S ^a,b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke; Systemic embolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG CHOICE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; LIVER FAILURE; NEOPLASM; OUTCOME ASSESSMENT; PATIENT SELECTION; RETREATMENT; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS; THROMBOSIS PREVENTION; TIME TO TREATMENT; AGE; AGED; CHEMICALLY INDUCED; COMORBIDITY; COMPLICATION; EMBOLISM; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; RISK FACTOR; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; EMBOLISM; HEMORRHAGE; HUMANS; MIDDLE AGED; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84942198634     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.07.003     Document Type: Article

References (183)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
2. Lip G.Y., Lim H.S. Atrial fibrillation and stroke prevention. Lancet Neurol 2007, 6(11):981-993.
3. Potpara T.S., Lip G.Y. Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation. Curr Pharm Des 2010, 16(31):3455-3471.
4. Gattellari M., Goumas C., Aitken R., Worthington J.M. Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (A Program of Research Informing Stroke Management). Cerebrovasc Dis 2011, 32(4):370-382.
5. Marini C., De Santis F., Sacco S., et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005, 36(6):1115-1119.
6. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857-867.
7. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
8. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
9. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
10. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369(22):2093-2104.
11. Friberg L., Rosenqvist M., Lip G.Y. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012, 125(19):2298-2307.
12. Olesen J.B., Lip G.Y.H., Lindhardsen J., et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011, 106(10):739-749.
13. Banerjee A., Lane D.A., Torp-Pedersen C., Lip G.Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012, 107(3):584-589.
14. Skjøth F., Larsen T.B., Rasmussen L.H., Lip G.Y.H. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014, 111(5):981-988.
15. De Caterina R., Husted S., Wallentin L., et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013, 110(6):1087-1107.
16. Lip G.Y.H., Andreotti F., Fauchier L., et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011, 106(12):997-1011.
17. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33(21):2719-2747.
18. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28(2):125-136.
19. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014.
20. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138(5):1093-1100.
21. Roldan V., Marin F., Fernandez H., et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013, 143(1):179-184.
22. Wilke T., Groth A., Mueller S., et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012, 107(6):1053-1065.
23. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370(9586):493-503.
24. Stroke Risk in Atrial Fibrillation Working G Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69(6):546-554.
25. Hughes M., Lip G.Y., Guideline Development Group NCGfMoAFiP, Secondary Care NIfH, Clinical E Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008, 99(2):295-304.
26. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987, 147(9):1561-1564.
27. Agarwal S., Hachamovitch R., Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012, 172(8):623-631. [discussion 631-3].
28. Hylek E.M., Evans-Molina C., Shea C., Henault L.E., Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115(21):2689-2696.
29. Kaplan R.C., Heckbert S.R., Koepsell T.D., et al. Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc 2001, 49(2):126-133.
30. Go A.S., Hylek E.M., Borowsky L.H., Phillips K.A., Selby J.V., Singer D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131(12):927-934.
31. Hylek E.M., D'Antonio J., Evans-Molina C., Shea C., Henault L.E., Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006, 37(4):1075-1080.
32. Lip G.Y., Laroche C., Dan G.A., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014, 16(3):308-319.
33. van Walraven C., Hart R.G., Singer D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002, 288(19):2441-2448.
34. Rash A., Downes T., Portner R., Yeo W.W., Morgan N., Channer K.S. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007, 36(2):151-156.
35. Lane D.A., Lip G.Y. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008, 39(1):7-9.
36. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40(6):675-683.
37. Abdel-Latif A.K., Peng X., Messinger-Rapport B.J. Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation. J Am Med Dir Assoc 2005, 6(2):128-131.
38. Gallagher A.M., Setakis E., Plumb J.M., Clemens A., van Staa T.P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011, 106(5):968-977.
39. Wan Y., Heneghan C., Perera R., et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1(2):84-91.
40. Man-Son-Hing M., Nichol G., Lau A., Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159(7):677-685.
41. Gage B.F., Birman-Deych E., Kerzner R., Radford M.J., Nilasena D.S., Rich M.W. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005, 118(6):612-617.
42. Sellers M.B., Newby L.K. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J 2011, 161(2):241-246.
43. Banerjee A., Clementy N., Haguenoer K., Fauchier L., Lip G.Y. Prior history of falls and risk of outcomes in atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Am J Med 2014, 127:972-978.
44. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123(21):2363-2372.
45. Goodman S.G., Wojdyla D.M., Piccini J.P., et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014, 63(9):891-900.
46. Hylek E.M., Held C., Alexander J.H., et al. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014, 63(20):2141-2147.
47. Halvorsen S., Atar D., Yang H., et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014, 35(28):1864-1872.
48. Halperin J.L., Hankey G.J., Wojdyla D.M., et al. Efficacy and Safety of Rivaroxaban Compared with Warfarin among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET AF Trial. Circulation 2014, 130:138-146.
49. Halperin JL W.D., Piccini J.P., Lokhnygina Y., et al. Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial. Stroke 2012, 43(A148).
50. Hankey G.J., Stevens S.R., Piccini J.P., et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014, 45(5):1304-1312.
51. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364(9):806-817.
52. Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014, 383(9921):955-962.
53. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011, 57(12):1339-1348.
54. Jonsson K.M., Wieloch M., Sterner G., et al. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden. Thromb Res 2011, 128(4):341-345.
55. Alonso A., Lopez F.L., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011, 123(25):2946-2953.
56. Soliman E.Z., Prineas R.J., Go A.S., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010, 159(6):1102-1107.
57. Genovesi S., Vincenti A., Rossi E., et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008, 51(2):255-262.
58. Ball J., Carrington M.J., McMurray J.J., Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013, 167(5):1807-1824.
59. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012, 367(7):625-635.
60. Lee M., Saver J.L., Chang K.H., Liao H.W., Chang S.C., Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010, 341:c4249.
61. Go A.S., Fang M.C., Udaltsova N., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009, 119(10):1363-1369.
62. Wizemann V., Tong L., Satayathum S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010, 77(12):1098-1106.
63. To A.C., Yehia M., Collins J.F. Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply?. Nephrology (Carlton) 2007, 12(5):441-447.
64. Wiesholzer M., Harm F., Tomasec G., Barbieri G., Putz D., Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 2001, 21(1):35-39.
65. Knoll F., Sturm G., Lamina C., et al. Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant 2012, 27(1):332-337.
66. Roldan V., Marin F., Fernandez H., et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013, 111(8):1159-1164.
67. Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011, 58(4):395-401.
68. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011, 6(11):2599-2604.
69. Hijazi Z., Hohnloser S.H., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014, 129(9):961-970.
70. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32(19):2387-2394.
71. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012, 33(22):2821-2830.
72. Eikelboom J.W., Connolly S.J., Gao P., et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012, 21(6):429-435.
73. Huber K., Connolly S.J., Kher A., et al. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract 2013, 67(6):516-526.
74. Hart R.G., Eikelboom J.W., Brimble K.S., McMurtry M.S., Ingram A.J. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013, 29(7 Suppl.):S71-S78.
75. Winkelmayer W.C., Liu J., Setoguchi S., Choudhry N.K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011, 6(11):2662-2668.
76. Chan K.E., Lazarus J.M., Thadhani R., Hakim R.M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009, 20(10):2223-2233.
77. Herzog C.A., Asinger R.W., Berger A.K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011, 80(6):572-586.
78. Capodanno D., Angiolillo D.J. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012, 125(21):2649-2661.
79. Schulman S. New oral anticoagulant agents - general features and outcomes in subsets of patients. Thromb Haemost 2014, 111(4):575-582.
80. Lahaye S., Regpala S., Lacombe S., et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014, 111(3):465-473.
81. Lane D.A., Lip G.Y.H. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014, 111(3):381-383.
82. Boriani G., Savelieva I., Dan G.A., et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015, [pii: euv202, Epub ahead of print].
83. Hankey G.J. Secondary stroke prevention. Lancet Neurol 2014, 13(2):178-194.
84. Palareti G., Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009, 102(2):268-278.
85. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342(8882):1255-1262.
86. Connolly S.J., Eikelboom J.W., Ng J., et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011, 155(9):579-586.
87. Morocutti C., Amabile G., Fattapposta F., et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997, 28(5):1015-1021.
88. Healey J.S., Hart R.G., Pogue J., et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008, 39(5):1482-1486.
89. Diener H.C., Connolly S.J., Ezekowitz M.D., et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9(12):1157-1163.
90. Hankey G.J., Patel M.R., Stevens S.R., et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012, 11(4):315-322.
91. Easton J.D., Lopes R.D., Bahit M.C., et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012, 11(6):503-511.
92. Diener H.C., Eikelboom J., Connolly S.J., et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012, 11(3):225-231.
93. Ntaios G., Papavasileiou V., Diener H.C., Makaritsis K., Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012, 43(12):3298-3304.
94. Diener H.C. Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.". Thromb Haemost 2013, 110(3):493-495.
95. Chandratheva A., Mehta Z., Geraghty O.C., Marquardt L., Rothwell P.M., Oxford Vascular S Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 2009, 72(22):1941-1947.
96. Wang Y., Wang Y., Zhao X., et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013, 369(1):11-19.
97. Paciaroni M., Agnelli G., Micheli S., Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007, 38(2):423-430.
98. Stollberger C., Finsterer J. Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation". Thromb Haemost 2013, 110(3):496-500.
99. Shibazaki K., Kimura K., Aoki J., Saji N., Sakai K. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013, 331(1-2):90-93.
100. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013, 15(5):625-651.
101. Kernan W.N., Ovbiagele B., Black H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014, 45(7):2160-2236.
102. Feigin V.L., Lawes C.M., Bennett D.A., Barker-Collo S.L., Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009, 8(4):355-369.
103. Flaherty M.L., Kissela B., Woo D., et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007, 68(2):116-121.
104. Huhtakangas J., Tetri S., Juvela S., Saloheimo P., Bode M.K., Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011, 42(9):2431-2435.
105. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120(8):700-705.
106. Rosand J., Eckman M.H., Knudsen K.A., Singer D.E., Greenberg S.M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164(8):880-884.
107. Fang M.C., Go A.S., Chang Y., et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012, 43(7):1795-1799.
108. Fihn S.D., McDonell M., Martin D., et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993, 118(7):511-520.
109. van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993, 153(13):1557-1562.
110. Poli D., Antonucci E., Grifoni E., Abbate R., Gensini G.F., Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009, 54(11):999-1002.
111. Charidimou A., Shakeshaft C., Werring D.J. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol 2012, 3:133.
112. Huttner H.B., Schellinger P.D., Hartmann M., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37(6):1465-1470.
113. Flaherty M.L., Tao H., Haverbusch M., et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008, 71(14):1084-1089.
114. Hart R.G., Tonarelli S.B., Pearce L.A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36(7):1588-1593.
115. Curtze S., Strbian D., Meretoja A., et al. Higher baseline international normalized ratio value correlates with higher mortality in intracerebral hemorrhage during warfarin use. Eur J Neurol 2014, 21(4):616-622.
116. Liotta E.M., Prabhakaran S. Warfarin-associated intracerebral hemorrhage is increasing in prevalence in the United States. J Stroke Cerebrovasc Dis 2013, 22(7):1151-1155.
117. Hart R.G., Diener H.C., Yang S., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43(6):1511-1517.
118. Alonso A., Bengtson L.G., MacLehose R.F., Lutsey P.L., Chen L.Y., Lakshminarayan K. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke 2014, 45(8):2286-2291.
119. Lauer A., Pfeilschifter W., Schaffer C.B., Lo E.H., Foerch C. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol 2013, 12(4):394-405.
120. Flaherty M.L., Haverbusch M., Sekar P., et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006, 5(3):197-201.
121. Toyoda K., Yasaka M., Nagata K., et al. Bleeding with Antithrombotic Therapy Study G. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The Bleeding with Antithrombotic Therapy (BAT) Retrospective Study. Cerebrovasc Dis 2009, 27(2):151-159.
122. Hua Y., Keep R.F., Hoff J.T., Xi G. Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke 2007, 38(2 Suppl.):759-762.
123. Levine J.M., Snider R., Finkelstein D., et al. Early edema in warfarin-related intracerebral hemorrhage. Neurocrit Care 2007, 7(1):58-63.
124. Lauer A., Cianchetti F.A., Van Cott E.M., et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011, 124(15):1654-1662.
125. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42(12):3594-3599.
126. Zhou W., Zorn M., Nawroth P., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013, 44(3):771-778.
127. Song T.J., Kim J., Lee H.S., et al. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation. Eur J Neurol 2013, 20(3):502-508.
128. Wong K.S., Chan Y.L., Liu J.Y., Gao S., Lam W.W. Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology 2003, 60(3):511-513.
129. Lee S.H., Ryu W.S., Roh J.K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 2009, 72(2):171-176.
130. Lovelock C.E., Cordonnier C., Naka H., Al-Shahi Salman R., Sudlow C.L., Edinburgh Stroke Study Group, Sprimachi T., Werring D.J., Gregoire S.M., Imaizumi T., Lee SH, Briley D., Rothwell P.M. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010, 41(6):1222-1228.
131. Diener H.C., Stanford S., Abdul-Rahim A., et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Rev Neurother 2014, 1-10.
132. Thijs V., Lemmens R., Schoofs C., et al. Microbleeds and the risk of recurrent stroke. Stroke 2010, 41(9):2005-2009.
133. Nielsen V.G., Cohen B.M., Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005, 49(2):222-231.
134. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127.
135. Wienen W., Stassen J.M., Priepke H., Ries U.J., Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007, 98(1):155-162.
136. Wienen W., Stassen J.M., Priepke H., Ries U.J., Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007, 98(2):333-338.
137. Sun L., Zhou W., Ploen R., Zorn M., Veltkamp R. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 2013, 110(1):153-161.
138. Morgenstern L.B., Hemphill J.C., Anderson C., et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 41(9):2108-2129.
139. Dowlatshahi D., Butcher K.S., Asdaghi N., et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012, 43(7):1812-1817.
140. Monroe D.M. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008, 45(2 Suppl. 1):S7-S11.
141. Makris M., Greaves M., Phillips W.S., Kitchen S., Rosendaal F.R., Preston E.F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77(3):477-480.
142. Mayer S.A., Brun N.C., Begtrup K., et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008, 358(20):2127-2137.
143. Woo C.H., Patel N., Conell C., et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg 2014, 81(1):110-115.
144. Foerch C., Arai K., Van Cott E.M., van Leyen K., Lo E.H. Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage. J Cereb Blood Flow Metab 2009, 29(5):1015-1021.
145. Illanes S., Zhou W., Schwarting S., Heiland S., Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011, 42(1):191-195.
146. Schlunk F., Van Cott E.M., Hayakawa K., Pfeilschifter W., Lo E.H., Foerch C. Recombinant activated coagulation factor VII and prothrombin complex concentrates are equally effective in reducing hematoma volume in experimental warfarin-associated intracerebral hemorrhage. Stroke 2012, 43(1):246-249.
147. Dickneite G., Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014, 111(2):189-198.
148. Sorensen B., Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006, 96(4):446-453.
149. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124(14):1573-1579.
150. Battinelli E.M. Reversal of new oral anticoagulants. Circulation 2011, 124(14):1508-1510.
151. Yung D., Kapral M.K., Asllani E., Fang J., Lee D.S., Investigators of the Registry of the Canadian Stroke N Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol 2012, 28(1):33-39.
152. Majeed A., Kim Y.K., Roberts R.S., Holmstrom M., Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010, 41(12):2860-2866.
153. Eckman M.H., Rosand J., Knudsen K.A., Singer D.E., Greenberg S.M. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003, 34(7):1710-1716.
154. Paciaroni M., Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?. Thromb Haemost 2014, 111(1):14-18.
155. Lanas A., Garcia-Rodriguez L.A., Polo-Tomas M., et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009, 104(7):1633-1641.
156. Coleman C.I., Sobieraj D.M., Winkler S., et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012, 66(1):53-63.
157. Hallas J., Dall M., Andries A., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006, 333(7571):726.
158. Lanas A., Wu P., Medin J., Mills E.J. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011, 9(9):762-768 e6.
159. Holster I.L., Valkhoff V.E., Kuipers E.J., Tjwa E.T. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013, 145(1):105-112 e15.
160. Desai J., Granger C.B., Weitz J.I., Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013, 78(2):227-239.
161. Larsen T.B., Rasmussen L.H., Skjoth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61(22):2264-2273.
162. Nessel C., Mahaffey K., Piccini J., Pan G., Patel M.R., Becker R. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET-AF trial. Chest 2012, 142(4_MeetingAbstracts):84A.
163. Witt D.M., Delate T., Garcia D.A., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012, 172(19):1484-1491.
164. Committee ASoP, Anderson M.A., Ben-Menachem T., et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009, 70(6):1060-1070.
165. Le Couteur D.G., Fraser R., Hilmer S., Rivory L.P., McLean A.J. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005, 44(2):187-200.
166. Roberts L.N., Patel R.K., Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010, 148(4):507-521.
167. Demirkan K., Stephens M.A., Newman K.P., Self T.H. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000, 93(5):448-454. [quiz 455].
168. Efird L.M., Mishkin D.S., Berlowitz D.R., et al. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes 2014, 7(3):461-467.
169. Graff J., Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013, 52(4):243-254.
170. Stangier J., Stahle H., Rathgen K., Roth W., Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008, 48(12):1411-1419.
171. Kubitza D., Roth A., Becka M., et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013, 76(1):89-98.
172. Raghavan N., Frost C.E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37(1):74-81.
173. Caldeira D., Barra M., Santos A.T., et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014, 100(7):550-556.
174. Kamphuisen P.W., Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res 2014, 133(Suppl. 2):S49-S55.
175. Trujillo-Santos J., Nieto J.A., Tiberio G., et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100(3):435-439.
176. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013, 144(5):1555-1563.
177. Skov J., Bladbjerg E.M., Bor M.V., Gram J. SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014, 145(1):187-188.
178. Poli D., Antonucci E., Testa S., Lip G.Y. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014, 9(4):443-447.
179. Gallego P., Roldan V., Marin F., et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014, 127(11):1083-1088.
180. Lip G.Y., Haguenoer K., Saint-Etienne C., Fauchier L. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014, 146(3):719-726.
181. Qaseem A., Hopkins R.H., Sweet D.E., Starkey M., Shekelle P., Clinical Guidelines Committee of the American College of P Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013, 159(12):835-847.
182. Investigators A., Connolly S.J., Pogue J., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360(20):2066-2078.
183. Investigators AWGotA, Connolly S., Pogue J., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367(9526):1903-1912.